17:46 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
00:51 , Dec 4, 2018 |  BC Extra  |  Clinical News

Weekend ASH presentations hint at future of BCMA CARs

Enhanced persistence and redirection of universal cells are among approaches companies are using to create the next generation of BCMA (tumor necrosis factor receptor superfamily member 17; TNFRSF17; CD269)-targeted CAR T cell therapies for multiple...
21:53 , Apr 13, 2018 |  BioCentury  |  Product Development

Self-driving CARs

Novartis AG, Gilead Sciences Inc. and now Pfizer Inc. have taken different approaches to managing their CAR T cell assets, but the three companies appear to be converging on the notion that developing the technology...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
22:08 , Dec 9, 2016 |  BC Week In Review  |  Clinical News

CART-BCMA: Preliminary Ph I data

Preliminary data from 6 evaluable patients with relapsed or refractory MM in an open-label, U.S. Phase I trial showed that IV CART-BCMA over 3 days led to 1 stringent complete response, 1 very good partial...
00:22 , Dec 7, 2016 |  BC Extra  |  Clinical News

BCMA-targeting therapies in ASH spotlight

At the American Society of Hematology meeting in San Diego, presentations late Monday highlighted data from Phase I studies of two candidates targeting tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17 ; CD269)...